OBJECTIVES: To assess the comparative efficacy and safety of monoclonal antibodies and a tyrosine-kinase inhibitor for severe or uncontrolled asthma, using a Bayesian network meta-analysis. METHODS: A systematic literature review was conducted according to NICE guidelines. Outcomes of interest included asthma control questionnaire (ACQ) score, asthma exacerbations and discontinuations due to adverse events (AE). Identified studies assessed mepolizumab, lebrikizumab, omalizumab and masitinib. Networks of evidence were based on treatment- and dose-specific nodes except for masitinib (results were only reported for pooled doses). Interpretation of results was based on absolute differences/ratios and Bayesian probabilities for treatments to perform better than others (P), where P≤15% indicated a smaller effect and P≥85% a larger effect. Vague prior distributions were used. RESULTS: D) at 16 weeks; at 52 weeks, omalizumab performed better than mepolizumab 75mg and 750mg (D=-0.25 and ‑0.20 respectively, P≥86%), and was comparable to mepolizumab 250mg (D=-0.13, P=75%). All active treatments performed better than placebo. In terms of asthma exacerbations, at 16 weeks, omalizumab was comparable to masitinib (OR=1.30, P=64%) and performed better than placebo, while masitinib was comparable to placebo (OR=0.60, P=76%). At 26 weeks, omalizumab performed better than placebo. At 16 and 26 weeks, active treatments and placebo had comparable discontinuations due to AE rates. At 52 weeks, mepolizumab 75mg had lower discontinuations due to AE rates than mepolizumab 750mg, and was comparable to other treatments. Omalizumab, mepolizumab 250mg, 750mg and placebo were comparable. CONCLUSIONS: This network meta-analysis of asthma treatments suggested that omalizumab had greater ACQ score reductions at 52 weeks than mepolizumab 75mg and 750mg but was comparable to mepolizumab 250mg. Active treatments were comparable regarding asthma exacerbations and discontinuations due to AE.